Discovery of novel SOS1 inhibitors using machine learning

Lihui Duo,Yi Chen,Qiupei Liu,Zhangyi Ma,Amin Farjudian,Wan Yong Ho,Sze Shin Low,Jianfeng Ren,Jonathan D. Hirst,Hua Xie,Bencan Tang

DOI: https://doi.org/10.1039/d4md00063c

2024-01-01

RSC Medicinal Chemistry

Abstract:Machine learning enabled ligand-based virtual screening is a valuable tool in discovering effective SOS1 inhibitors.

biochemistry & molecular biology,chemistry, medicinal

What problem does this paper attempt to address?

Active Learning-Driven Discovery and Dynamics Simulation of Novel SQLE Inhibitors with ADMET Analysis and Molecular Modification

YunYun Xu,Qiang Wang,GaoQiang Xu,YouJian Xu,Yiping Mou

DOI: https://doi.org/10.21203/rs.3.rs-4163089/v1

2024-01-01

Abstract:Abstract In this study, we leveraged a sophisticated active learning model to enhance virtual screening for SQLE inhibitors. The model's improved predictive accuracy identified compounds with significant advantages in binding affinity and thermodynamic stability. Detailed analyses, including molecular dynamics simulations and ADMET profiling, were conducted, particularly focusing on compounds CMNPD11566 and its derivative HCJ007. CMNPD11566 showed stable interactions with SQLE, but HCJ007 exhibited enhanced dynamic characteristics and interaction patterns. ADMET data comparison highlighted HCJ007's superior profile in terms of lower toxicity and better drug-likeness. Our findings suggest HCJ007 as a promising candidate for SQLE inhibition, with significant improvements over CMNPD11566 in various pharmacokinetic and safety parameters. The study underscores the efficacy of computational models in drug discovery and the importance of comprehensive preclinical evaluations.
Discovery of novel ULK1 inhibitors through machine learning-guided virtual screening and biological evaluation

Miao-Miao Kong,Tao Wei,Bo Liu,Zi-Xuan Xi,Jun-Tao Ding,Xin Liu,Ke Li,Tian-Li Qin,Zhen-Yong Qian,Wen-Can Wu,Jian-Zhang Wu,Wu-Lan Li

DOI: https://doi.org/10.1080/17568919.2024.2385288

2024-08-15

Abstract:Aim: Build a virtual screening model for ULK1 inhibitors based on artificial intelligence. Materials & methods: Build machine learning and deep learning classification models and combine molecular docking and biological evaluation to screen ULK1 inhibitors from 13 million compounds. And molecular dynamics was used to explore the binding mechanism of active compounds. Results & conclusion: Possibly due to less available training data, machine learning models significantly outperform deep learning models. Among them, the Naive Bayes model has the best performance. Through virtual screening, we obtained three inhibitors with IC50 of μM level and they all bind well to ULK1. This study provides an efficient virtual screening model and three promising compounds for the study of ULK1 inhibitors.
Screening, Optimization, and ADMET Evaluation of HCJ007 for Pancreatic Cancer Treatment Through Active Learning and Dynamics Simulation

YunYun Xu,Qiang Wang,GaoQiang Xu,YouJian Xu,YiPing Mou

DOI: https://doi.org/10.3389/fchem.2024.1482758

IF: 5.5

2024-01-01

Frontiers in Chemistry

Abstract:In this study, we leveraged a sophisticated active learning model to enhance virtual screening for SQLE inhibitors. The model’s improved predictive accuracy identified compounds with significant advantages in binding affinity and thermodynamic stability. Detailed analyses, including molecular dynamics simulations and ADMET profiling, were conducted, particularly focusing on compounds CMNPD11566 and its derivative HCJ007. CMNPD11566 showed stable interactions with SQLE, while HCJ007 exhibited improved binding stability and more frequent interactions with key residues, indicating enhanced dynamic adaptability and overall binding effectiveness. ADMET data comparison highlighted HCJ007s superior profile in terms of lower toxicity and better drug-likeness. Our findings suggest HCJ007 as a promising candidate for SQLE inhibition, with significant improvements over CMNPD11566 in various pharmacokinetic and safety parameters. The study underscores the efficacy of computational models in drug discovery and the importance of comprehensive preclinical evaluations.
Identifying Potential SOS1 Inhibitors via Virtual Screening of Multiple Small Molecule Libraries against KRAS‐SOS1 Interface

Saima Ikram,Ehsan Sayyah,Serdar Durdagi

DOI: https://doi.org/10.1002/cbic.202400008

IF: 3.2

2024-04-16

ChemBioChem

Abstract:The RAS‐MAPK signaling pathway, crucial for cell proliferation and differentiation, involves key proteins KRAS and SOS1. Mutations in the KRAS and SOS1 genes are implicated in various cancer types, including pancreatic, lung, and juvenile myelomonocytic leukemia. There is considerable interest in identifying inhibitors targeting KRAS and SOS1 to explore potential therapeutic strategies for cancer treatment. In this study, advanced in silico techniques were employed to screen small molecule libraries at this interface, leading to the identification of promising lead compounds as potential SOS1 inhibitors. Comparative analysis of the average binding free energies of these predicted potent compounds with known SOS1 small molecule inhibitors revealed that the identified compounds display similar or even superior predicted binding affinities compared to the known inhibitors. These findings offer valuable insights into the potential of these compounds as candidates for further development as effective anti‐cancer agents.

biochemistry & molecular biology,chemistry, medicinal
Novel potent SOS1 inhibitors containing a tricyclic quinazoline scaffold: a joint view of experiments and simulations

Luolong Qing,Zhengzai Cheng,Juan Xu,Ziwei Wang,Yuanyuan Li,Mario Gauthier,Silong Zhang,Huan He

DOI: https://doi.org/10.1016/j.ejmech.2024.117065

IF: 7.088

2024-11-24

European Journal of Medicinal Chemistry

Abstract:Small molecules that possess the ability to regulate the interactions between Son of Sevenless 1 (SOS1) and Kristen rat sarcoma (KRAS) offer immense potential in the realm of cancer therapy. In this study, we present a novel series of SOS1 inhibitors featuring a tricyclic quinazoline scaffold. Notably, we have identified compound 8d , which demonstrates the highest potency with an IC 50 value of 5.1 nM for disrupting the KRAS:SOS1 interaction. Compound 8d exhibits a promising pharmacokinetic profile and achieves a remarkable 70.5 % inhibition of tumor growth in pancreas tumor xenograft models. Furthermore, molecular dynamic simulations have unveiled that the tricyclic quinazoline derivatives exhibit extensive interaction with Tyr884, a crucial residue for the recognition between SOS1 and KRAS. Our findings provide fresh insights into the design of future SOS1 inhibitors, paving the way for innovative therapeutic strategies.

chemistry, medicinal
Discovery of indoleamine 2,3-dioxygenase inhibitors using machine learning based virtual screening

Hongao Zhang,Wei Liu,Zhihong Liu,Yingchen Ju,Mengyang Xu,Yue Zhang,Xinyu Wu,Qiong Gu,Zhong Wang,Jun Xu

DOI: https://doi.org/10.1039/c7md00642j

2018-03-01

MedChemComm

Abstract:Indoleamine 2,3-dioxygenase (IDO), an immune checkpoint, is a promising target for cancer immunotherapy. However, current IDO inhibitors are not approved for clinical use yet; therefore, new IDO inhibitors are still demanded. To identify new IDO inhibitors, we have built naive Bayesian (NB) and recursive partitioning (RP) models from a library of known IDO inhibitors derived from recent publications. Thirteen molecular fingerprints were used as descriptors for the models to predict IDO inhibitors. An in-house compound library was virtually screened using the best machine learning model, which resulted in 50 hits for further enzyme-based IDO inhibitory assays. Consequently, we identified three new IDO inhibitors with IC50 values of 1.30, 4.10, and 4.68 μM. These active compounds also showed IDO inhibitory activities in cell-based assays. The compounds belong to the tanshinone family, a typical scaffold family derived from Danshen (a Chinese herb), the dried root of Salvia miltiorrhiza, which has been widely used in China, Japan, the United States, and other European countries for the treatment of cardiovascular and cerebrovascular diseases. Thus, we discovered a new use for Danshen using machine learning methods. Surface plasmon resonance (SPR) experiments proved that the inhibitors interacted with the IDO target. Molecular dynamic simulations demonstrated the binding modes of the IDO inhibitors.
Consensus holistic virtual screening for drug discovery: a novel machine learning model approach

Said Moshawih,Zhen Hui Bu,Hui Poh Goh,Nurolaini Kifli,Lam Hong Lee,Khang Wen Goh,Long Chiau Ming

DOI: https://doi.org/10.1186/s13321-024-00855-8

2024-05-30

Journal of Cheminformatics

Abstract:In drug discovery, virtual screening is crucial for identifying potential hit compounds. This study aims to present a novel pipeline that employs machine learning models that amalgamates various conventional screening methods. A diverse array of protein targets was selected, and their corresponding datasets were subjected to active/decoy distribution analysis prior to scoring using four distinct methods: QSAR, Pharmacophore, docking, and 2D shape similarity, which were ultimately integrated into a single consensus score. The fine-tuned machine learning models were ranked using the novel formula "w_new", consensus scores were calculated, and an enrichment study was performed for each target. Distinctively, consensus scoring outperformed other methods in specific protein targets such as PPARG and DPP4, achieving AUC values of 0.90 and 0.84, respectively. Remarkably, this approach consistently prioritized compounds with higher experimental PIC 50 values compared to all other screening methodologies. Moreover, the models demonstrated a range of moderate to high performance in terms of R 2 values during external validation. In conclusion, this novel workflow consistently delivered superior results, emphasizing the significance of a holistic approach in drug discovery, where both quantitative metrics and active enrichment play pivotal roles in identifying the best virtual screening methodology.

chemistry, multidisciplinary,computer science, interdisciplinary applications, information systems
De Novo Generation and Identification of Novel Compounds with Drug Efficacy Based on Machine Learning

Dakuo He,Qing Liu,Yan Mi,Qingqi Meng,Libin Xu,Chunyu Hou,Jinpeng Wang,Ning Li,Yang Liu,Huifang Chai,Yanqiu Yang,Jingyu Liu,Lihui Wang,Yue Hou

DOI: https://doi.org/10.1002/advs.202307245

IF: 15.1

2024-01-12

Advanced Science

Abstract:A machine learning‐based strategy for de novo generation of novel compounds with drug efficacy termed DTLS is proposed, which exhibits the advantage of directly generating molecules with desired drug efficacy by taking dataset of disease‐direct‐related activity, independent of target protein, as input, and proven to be effective for rapid generation and identification of desired lead compounds evidenced by wet experiments. One of the main challenges in small molecule drug discovery is finding novel chemical compounds with desirable activity. Traditional drug development typically begins with target selection, but the correlation between targets and disease remains to be further investigated, and drugs designed based on targets may not always have the desired drug efficacy. The emergence of machine learning provides a powerful tool to overcome the challenge. Herein, a machine learning‐based strategy is developed for de novo generation of novel compounds with drug efficacy termed DTLS (Deep Transfer Learning‐based Strategy) by using dataset of disease‐direct‐related activity as input. DTLS is applied in two kinds of disease: colorectal cancer (CRC) and Alzheimer's disease (AD). In each case, novel compound is discovered and identified in in vitro and in vivo disease models. Their mechanism of actionis further explored. The experimental results reveal that DTLS can not only realize the generation and identification of novel compounds with drug efficacy but also has the advantage of identifying compounds by focusing on protein targets to facilitate the mechanism study. This work highlights the significant impact of machine learning on the design of novel compounds with drug efficacy, which provides a powerful new approach to drug discovery.

materials science, multidisciplinary,nanoscience & nanotechnology,chemistry
Current advances and development strategies of targeting son of sevenless 1 (SOS1) in drug discovery

Jialin Wu,Xiaoxue Li,Chengyong Wu,Yuxi Wang,Jifa Zhang

DOI: https://doi.org/10.1016/j.ejmech.2024.116282

2024-03-15

Abstract:The Son of Sevenless 1 (SOS1) guanine nucleotide exchange factor, prevalent across eukaryotic species, plays a pivotal role in facilitating the attachment of RAS protein to GTP, thereby regulating the activation of intracellular RAS proteins. This regulation is part of a feedback mechanism involving SOS1, which allows both activators and inhibitors of SOS1 to exert control over downstream signaling pathways, demonstrating potential anti-tumor effects. Predominantly, small molecule modulators that target SOS1 focus on a hydrophobic pocket within the CDC25 protein domain. The effectiveness of these modulators largely depends on their ability to interact with specific amino acids, notably Phe890 and Tyr884. This interaction is crucial for influencing the protein-protein interaction (PPI) between RAS and the catalytic domain of SOS1. Currently, most small molecule modulators targeting SOS1 are in the preclinical research phase, with a few advancing to clinical trials. This progression raises safety concerns, making the assurance of drug safety a primary consideration alongside the enhancement of efficacy in the development of SOS1 modulators. This review encapsulates recent advancements in the chemical categorization of SOS1 inhibitors and activators. It delves into the evolution of small molecule modulation targeting SOS1 and offers perspectives on the design of future generations of selective SOS1 small molecule modulators.
Comparative analysis of machine learning methods in ligand-based virtual screening of large compound libraries.

Xiao H Ma,Jia Jia,Feng Zhu,Ying Xue,Ze R Li,Yu Z Chen

DOI: https://doi.org/10.2174/138620709788167944

2009-01-01

Combinatorial Chemistry & High Throughput Screening

Abstract:Machine learning methods have been explored as ligand-based virtual screening tools for facilitating drug lead discovery. These methods predict compounds of specific pharmacodynamic, pharmacokinetic or toxicological properties based on their structure-derived structural and physicochemical properties. Increasing attention has been directed at these methods because of their capability in predicting compounds of diverse structures and complex structure-activity relationships without requiring the knowledge of target 3D structure. This article reviews current progresses in using machine learning methods for virtual screening of pharmacodynamically active compounds from large compound libraries, and analyzes and compares the reported performances of machine learning tools with those of structure-based and other ligand-based (such as pharmacophore and clustering) virtual screening methods. The feasibility to improve the performance of machine learning methods in screening large libraries is discussed.
Highly Selective Novel Heme Oxygenase-1-Targeting Molecules Discovered by DNA-Encoded Library-Machine Learning Model beyond the DEL Chemical Space

Shuai Han,Xinyun Guo,Min Wang,Huan Liu,Yidan Song,Yunyun He,Kuang-Lung Hsueh,Weiren Cui,Wenji Su,Letian Kuai,Jason Deng

DOI: https://doi.org/10.26434/chemrxiv-2024-k5v0s

2024-03-07

Abstract:DNA-encoded library (DEL) technology has proven to be a powerful method for discovering novel inhibitors for diverse targets. Particularly when combined with machine learning (ML), the DEL-ML workflow expands the chemical space and enhances cost-effectiveness, offering new opportunities to find desired hit molecules. Heme oxygenase-1 (HO-1), primarily a heme-degrading enzyme, has been identified as a potential therapeutic target in diseases such as cancer and neurodegenerative disorders. Despite years of study, the HO-1 inhibitor toolbox remains limited. Here, we report the discovery of five series of novel scaffold HO-1 inhibitors using a DEL-ML workflow that emphasizes the model’s uncertainty quantification and its domain of applicability. The DEL-ML model demonstrated a strong ability to extrapolate to novel chemical spaces by identifying new structures. Approximately 33% of the predicted molecules, validated by biophysical assays, had a binding affinity of K¬D < 15 µM, with the strongest affinity being 141 nM. Fourteen tested molecules showed over 100-fold selectivity towards HO-1 over Heme oxygenase-2 (HO-2). These molecules are also structurally novel compared to the reported HO-1 inhibitors. Further, binding mode simulations via docking provided insights into the possible selectivity rationale of some selective series.

Chemistry
Discovery of Five SOS2 Fragment Hits with Binding Modes Determined by SOS2 X-Ray Cocrystallography

Christopher R. Smith,Dan Chen,James G. Christensen,René Coulombe,James Féthière,Robin J. Gunn,Johan Hollander,Benjamin Jones,John M. Ketcham,Shilpi Khare,Jon Kuehler,J. David Lawson,Matthew A. Marx,Peter Olson,Kelly E. Pearson,Cynthia Ren,Denise Tsagris,Thirumalaiselvi Ulaganathan,Inge Van’t Veer,Xiaolun Wang,Anthony Ivetac

DOI: https://doi.org/10.1021/acs.jmedchem.3c02140

IF: 8.039

2024-01-03

Journal of Medicinal Chemistry

Abstract:SOS1 and SOS2 are guanine nucleotide exchange factors that mediate RTK-stimulated RAS activation. Selective SOS1:KRAS PPI inhibitors are currently under clinical investigation, whereas there are no reports to date of SOS2:KRAS PPI inhibitors. SOS2 activity is implicated in MAPK rebound when divergent SOS1 mutant cell lines are treated with the SOS1 inhibitor BI-3406; therefore, SOS2:KRAS inhibitors are of therapeutic interest. In this report, we detail a fragment-based screening strategy to...

chemistry, medicinal
Developing novel ligands with enhanced binding affinity for the sphingosine 1-phosphate receptor 1 using machine learning

Colin Zhang,Yang Ha

DOI: https://doi.org/10.48550/arXiv.2307.16037

2023-07-30

Abstract:Multiple sclerosis (MS) is a debilitating neurological disease affecting nearly one million people in the United States. Sphingosine-1-phosphate receptor 1, or S1PR1, is a protein target for MS. Siponimod, a ligand of S1PR1, was approved by the FDA in 2019 for MS treatment, but there is a demonstrated need for better therapies. To this end, we finetuned an autoencoder machine learning model that converts chemical formulas into mathematical vectors and generated over 500 molecular variants based on siponimod, out of which 25 compounds had higher predicted binding affinity to S1PR1. The model was able to generate these ligands in just under one hour. Filtering these compounds led to the discovery of six promising candidates with good drug-like properties and ease of synthesis. Furthermore, by analyzing the binding interactions for these ligands, we uncovered several chemical properties that contribute to high binding affinity to S1PR1. This study demonstrates that machine learning can accelerate the drug discovery process and reveal new insights into protein-drug interactions.

Machine Learning
Discovery of new STAT3 inhibitors as anticancer agents using ligand-receptor contact fingerprints and docking-augmented machine learning

Nour Jamal Jaradat,Walhan Alshaer,Mamon Hatmal,Mutasem Omar Taha

DOI: https://doi.org/10.1039/d2ra07007c

IF: 4.036

2023-02-04

RSC Advances

Abstract:STAT3 belongs to a family of seven vital transcription factors. High levels of STAT3 are detected in several types of cancer. Hence, STAT3 inhibition is considered a promising therapeutic anti-cancer strategy. In this work, we used multiple docked poses of STAT3 inhibitors to augment training data for machine learning QSAR modeling. Ligand–Receptor Contact Fingerprints and scoring values were implemented as descriptor variables. Escalating docking-scoring consensus levels were scanned against orthogonal machine learners, and the best learners (Random Forests and XGBoost) were coupled with genetic algorithm and Shapley additive explanations (SHAP) to identify critical descriptors that determine anti-STAT3 bioactivity to be translated into pharmacophore model(s). Two successful pharmacophores were deduced and subsequently used for in silico screening against the National Cancer Institute (NCI) database. A total of 26 hits were evaluated in vitro for their anti-STAT3 bioactivities. Out of which, three hits of novel chemotypes, showed cytotoxic IC 50 values in the nanomolar range (35 nM to 6.7 μM). However, two are potent dihydrofolate reductase (DHFR) inhibitors and therefore should have significant indirect STAT3 inhibitory effects. The third hit (cytotoxic IC 50 = 0.44 μM) is purely direct STAT3 inhibitor (devoid of DHFR activity) and caused, at its cytotoxic IC 50 , more than two-fold reduction in the expression of STAT3 downstream genes (c-Myc and Bcl-xL). The presented work indicates that the concept of data augmentation using multiple docked poses is a promising strategy for generating valid machine learning models capable of discriminating active from inactive compounds.

chemistry, multidisciplinary
Artificial intelligence for small molecule anticancer drug discovery

Lihui Duo Yu Liu Jianfeng Ren Bencan Tang Jonathan D. Hirst a Faculty of Science and Engineering,University of Nottingham Ningbo China,Ningbo,Chinab School of Chemistry,University of Nottingham University Park,Nottingham,UK

DOI: https://doi.org/10.1080/17460441.2024.2367014

2024-06-19

Expert Opinion on Drug Discovery

Abstract:Introduction The transition from conventional cytotoxic chemotherapy to targeted cancer therapy with small-molecule anticancer drugs has enhanced treatment outcomes. This approach, which now dominates cancer treatment, has its advantages. Despite the regulatory approval of several targeted molecules for clinical use, challenges such as low response rates and drug resistance still persist. Conventional drug discovery methods are costly and time-consuming, necessitating more efficient approaches. The rise of artificial intelligence (AI) and access to large-scale datasets have revolutionized the field of small-molecule cancer drug discovery. Machine learning (ML), particularly deep learning (DL) techniques, enables the rapid identification and development of novel anticancer agents by analyzing vast amounts of genomic, proteomic, and imaging data to uncover hidden patterns and relationships.

pharmacology & pharmacy
Highly Selective Novel Heme Oxygenase-1 Hits Found by DNA-Encoded Library Machine Learning beyond the DEL Chemical Space

Shuai Han,Xinyun Guo,Min Wang,Huan Liu,Yidan Song,Yunyun He,Kuang-Lung Hsueh,Weiren Cui,Wenji Su,Letian Kuai,Jason Deng

DOI: https://doi.org/10.1021/acsmedchemlett.4c00121

2024-08-21

Abstract:DNA-encoded library (DEL) technology, especially when combined with machine learning (ML), is a powerful method to discover novel inhibitors. DEL-ML can expand a larger chemical space and boost cost-effectiveness during hit finding. Heme oxygenase-1 (HO-1), a heme-degrading enzyme, is linked to diseases such as cancer and neurodegenerative disorders. The discovery of five series of new scaffold HO-1 hits is reported here, using a DEL-ML workflow, which emphasizes the model's uncertainty quantification and domain of applicability. This model exhibits a strong extrapolation ability, identifying new structures beyond the DEL chemical space. About 37% of predicted molecules showed a binding affinity of K D < 20 μM, with the strongest being 141 nM, amd 14 of those molecules displayed >100-fold selectivity for HO-1 over heme oxygenase-2 (HO-2). These molecules also showed structural novelty compared to existing HO-1 inhibitors. Docking simulations provided insights into possible selectivity rationale.
Discovery of senolytics using machine learning

Vanessa Smer-Barreto,Andrea Quintanilla,Richard J. R. Elliott,John C. Dawson,Jiugeng Sun,Víctor M. Campa,Álvaro Lorente-Macías,Asier Unciti-Broceta,Neil O. Carragher,Juan Carlos Acosta,Diego A. Oyarzún

DOI: https://doi.org/10.1038/s41467-023-39120-1

IF: 16.6

2023-06-11

Nature Communications

Abstract:Cellular senescence is a stress response involved in ageing and diverse disease processes including cancer, type-2 diabetes, osteoarthritis and viral infection. Despite growing interest in targeted elimination of senescent cells, only few senolytics are known due to the lack of well-characterised molecular targets. Here, we report the discovery of three senolytics using cost-effective machine learning algorithms trained solely on published data. We computationally screened various chemical libraries and validated the senolytic action of ginkgetin, periplocin and oleandrin in human cell lines under various modalities of senescence. The compounds have potency comparable to known senolytics, and we show that oleandrin has improved potency over its target as compared to best-in-class alternatives. Our approach led to several hundred-fold reduction in drug screening costs and demonstrates that artificial intelligence can take maximum advantage of small and heterogeneous drug screening data, paving the way for new open science approaches to early-stage drug discovery.

multidisciplinary sciences
Discovery of Novel Epidermal Growth Factor Receptor (EGFR) Inhibitors Using Computational Approaches

Donghui Huo,Shiyu Wang,Yue Kong,Zijian Qin,Aixia Yan

DOI: https://doi.org/10.1021/acs.jcim.1c00884

IF: 6.162

2021-12-21

Journal of Chemical Information and Modeling

Abstract:The epidermal growth factor receptor (EGFR) signaling pathway plays an important role in cell growth, proliferation, differentiation, and other physiological processes, which makes the EGFR a promising target for anticancer therapies. The discovery of novel EGFR inhibitors may provide a solution to the problem of drug resistance. In this work, we performed a ligand-based virtual screening (LBVS) protocol for finding novel EGFR inhibitors from a 5.3 million compound library. First, the 3D shape-based similarity was used to obtain structurally novel EGFR inhibitors. In this study, we tried three queries; two were crystal structures and one was generated from deep generative models of graphs (DGMG). Next, we have built four structure-activity relationship (SAR) models and three quantitative structure-activity relationship (QSAR) models based on an SVM method for further screening of highly active EGFR inhibitors. Experimental validations led to the identification of nine hits out of 18 tested compounds. Among them, hit 1, hit 5, and hit 6 had IC<sub>50</sub> values around 80 nM against EGFR whose interactions with EGFR were further investigated by molecular dynamics simulations.

chemistry, multidisciplinary, medicinal,computer science, interdisciplinary applications, information systems
Discovery of a Novel and Potent LCK Inhibitor for Leukemia Treatment Via Deep Learning and Molecular Docking.

Hao Guo,Zhe-yuan Shen,Yong-yi Yuan,Rou-fen Chen,Jing-yi Yang,Xing-chen Liu,Qing Zhang,Qian-ying Pan,Jian-jun Ding,Xin-jun He,Qing-nan Zhang,Xiao-wu Dong,Ke-shu Zhou

DOI: https://doi.org/10.1021/acs.jcim.4c00151

IF: 6.162

2024-01-01

Journal of Chemical Information and Modeling

Abstract:The lymphocyte-specific protein tyrosine kinase (LCK) plays a crucial role in both T-cell development and activation. Dysregulation of LCK signaling has been demonstrated to drive the oncogenesis of T-cell acute lymphoblastic leukemia (T-ALL), thus providing a therapeutic target for leukemia treatment. In this study, we introduced a sophisticated virtual screening strategy combined with biological evaluations to discover potent LCK inhibitors. Our initial approach involved utilizing the PLANET algorithm to assess and contrast various scoring methodologies suitable for LCK inhibitor screening. After effectively evaluating PLANET, we progressed to devise a virtual screening workflow that synergistically combines the strengths of PLANET with the capabilities of Schr & ouml;dinger's suite. This integrative strategy led to the efficient identification of four potential LCK inhibitors. Among them, compound 1232030-35-1 stood out as the most promising candidate with an IC50 of 0.43 nM. Further in vitro bioassays revealed that 1232030-35-1 exhibited robust antiproliferative effects on T-ALL cells, which was attributed to its ability to suppress the phosphorylations of key molecules in the LCK signaling pathway. More importantly, 1232030-35-1 treatment demonstrated profound in vivo antileukemia efficacy in a human T-ALL xenograft model. In addition, complementary molecular dynamics simulations provided deeper insight into the binding kinetics between 1232030-35-1 and LCK, highlighting the formation of a hydrogen bond with Met319. Collectively, our study established a robust and effective screening strategy that integrates AI-driven and conventional methodologies for the identification of LCK inhibitors, positioning 1232030-35-1 as a highly promising and novel drug-like candidate for potential applications in treating T-ALL.
Discovery of novel dual VEGFR2 and Src inhibitors using a multistep virtual screening approach

Chen Shangying,Qin Chu,Sin Jia En,Yang Xuan,Tao Lin,Zeng Xian,Zhang Peng,Gao Chun Mei,Jiang Yu Yang,Zhang Cheng,Chen Yu Zong,Chui Wai Keung

DOI: https://doi.org/10.4155/fmc-2016-0162

2017-01-01

Future Medicinal Chemistry

Abstract:Aim: Simultaneous inhibition of VEGFR2 and Src may enhance the efficacy of VEGFR2-targeted cancer therapeutics. Hence, development of dual inhibitors on VEGFR2 and Src can be a useful strategy for such treatments. Materials & methods: A multistep virtual screening protocol, comprising ligand-based support vector machines method, drug-likeness rules filter and structure-based molecular docking, was developed and employed to identify dual inhibitors of VEGFR2 and Src from a large commercial chemical library. Kinase inhibitory assays and cell viability assays were then used for experimental validation. Results: A set of compounds belonging to six different molecular scaffolds was identified and sent for biological evaluation. Compound 3c belonging to the 2-amino-3-cyanopyridine scaffold exhibited good antiproliferative effect and dual-target activities against VEGFR2 and Src. Conclusion: This study demonstrated the ability of the multistep virtual screening approach to identify novel multitarget agents. © 2017 Future Science Ltd.

Discovery of novel SOS1 inhibitors using machine learning

Active Learning-Driven Discovery and Dynamics Simulation of Novel SQLE Inhibitors with ADMET Analysis and Molecular Modification

Discovery of novel ULK1 inhibitors through machine learning-guided virtual screening and biological evaluation

Screening, Optimization, and ADMET Evaluation of HCJ007 for Pancreatic Cancer Treatment Through Active Learning and Dynamics Simulation

Identifying Potential SOS1 Inhibitors via Virtual Screening of Multiple Small Molecule Libraries against KRAS‐SOS1 Interface

Novel potent SOS1 inhibitors containing a tricyclic quinazoline scaffold: a joint view of experiments and simulations

Discovery of indoleamine 2,3-dioxygenase inhibitors using machine learning based virtual screening

Consensus holistic virtual screening for drug discovery: a novel machine learning model approach

De Novo Generation and Identification of Novel Compounds with Drug Efficacy Based on Machine Learning

Current advances and development strategies of targeting son of sevenless 1 (SOS1) in drug discovery

Comparative analysis of machine learning methods in ligand-based virtual screening of large compound libraries.

Highly Selective Novel Heme Oxygenase-1-Targeting Molecules Discovered by DNA-Encoded Library-Machine Learning Model beyond the DEL Chemical Space

Discovery of Five SOS2 Fragment Hits with Binding Modes Determined by SOS2 X-Ray Cocrystallography

Developing novel ligands with enhanced binding affinity for the sphingosine 1-phosphate receptor 1 using machine learning

Discovery of new STAT3 inhibitors as anticancer agents using ligand-receptor contact fingerprints and docking-augmented machine learning

Artificial intelligence for small molecule anticancer drug discovery

Highly Selective Novel Heme Oxygenase-1 Hits Found by DNA-Encoded Library Machine Learning beyond the DEL Chemical Space

Discovery of senolytics using machine learning

Discovery of Novel Epidermal Growth Factor Receptor (EGFR) Inhibitors Using Computational Approaches

Discovery of a Novel and Potent LCK Inhibitor for Leukemia Treatment Via Deep Learning and Molecular Docking.

Discovery of novel dual VEGFR2 and Src inhibitors using a multistep virtual screening approach